Andrea M. Allan

Andrea M. Allan

Auto-generated profile, based on publicly available information

Andrea M. Allan

Department of Neurosciences, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2014 in Current Environmental Health Reports
Verified
Journal Article
Open access
PDF file
CTChristina R. Tyler
Christina R. Tyler
AAAndrea M. Allan
Andrea M. Allan
Arsenic toxicity is a worldwide health concern as several millions of people are exposed to this toxicant via drinking water, and exposure affects almost every organ system in the body including the brain. Recent studies have shown that even low concentrations of arsenic impair neurological function, particularly in children. This review will focus on the current epidemiological evidence of arsenic neurotoxicity in children and adults, with emphasis on cognitive dysfunction, including learning and memory deficits and mood disorders. We provide a cohesive synthesis of the animal studies that have focused on neural mechanisms of dysfunction after arsenic exposure including altered epigenetics; hippocampal function; glucocorticoid and hypothalamus-pituitary-adrenal axis (HPA) pathway signaling; glutamatergic, cholinergic and monoaminergic signaling; adult neurogenesis; and increased Alzheimer’s-associated pathologies. Finally, we briefly discuss new studies focusing on therapeutic strategies to combat arsenic toxicity including the use of selenium and zinc.

16 November 1986 in Life Sciences
Verified
Journal Article
Closed access
AAAndrea M. Allan
Andrea M. Allan
RHR.Adron Harris
R.Adron Harris

1 August 1987 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
AAAndrea M. Allan
Andrea M. Allan
RHR.Adron Harris
R.Adron Harris

24 April 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
WGWeixiang Guo
Weixiang Guo
AAAndrea M Allan
Andrea M Allan
RZRuiting Zong
Ruiting Zong
LZLi Zhang
Li Zhang
EJEric B Johnson
Eric B Johnson
XZXinyu Zhao
Xinyu Zhao

2 November 2011 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
WGWeixiang Guo
Weixiang Guo
AMAdeline C. Murthy
Adeline C. Murthy
LZL. Zhang
L. Zhang
EJEric B. Johnson
Eric B. Johnson
ESEric G. Schaller
Eric G. Schaller
XZXinyu Zhao
Xinyu Zhao
Fragile X syndrome (FXS), a common inherited form of intellectual disability with learning deficits, results from a loss of fragile X mental retardation protein (FMRP). Despite extensive research, treatment options for FXS remain limited. Since FMRP is known to play an important role in adult hippocampal neurogenesis and hippocampus-dependent learning and FMRP regulates the adult neural stem cell fate through the translational regulation of glycogen synthase kinase 3β (GSK3β), we investigated the effects of a GSK3β inhibitor, SB216763, on Fmr1 knockout mice (Fmr1 KO). We found that the inhibition of GSK3β could reverse the hippocampus-dependent learning deficits and rescue adult hippocampal neurogenesis at multiple stages in Fmr1 KO mice. Our results point to GSK3β inhibition as a potential treatment for the learning deficits seen in FXS.

20 September 2011 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
MBMegan L. Brady
Megan L. Brady
AAAndrea M. Allan
Andrea M. Allan
KCKevin K. Caldwell
Kevin K. Caldwell